Evaluating surrogate endpoints
- 20 December 2002
- journal article
- editorial
- Published by Elsevier BV in Controlled Clinical Trials
- Vol. 23 (6), 703-707
- https://doi.org/10.1016/s0197-2456(02)00264-7
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Surrogate markers and joint models for longitudinal and survival dataControlled Clinical Trials, 2002
- Statistical challenges in the evaluation of surrogate endpoints in randomized trialsControlled Clinical Trials, 2002
- Survival Analysis Using Auxiliary Variables Via Multiple Imputation, with Application to AIDS Clinical Trial DataBiometrics, 2002
- On meta-analytic assessment of surrogate outcomesBiostatistics, 2000
- Human Immunodeficiency Virus Type 1 RNA Level and CD4 Count as Prognostic Markers and Surrogate End Points: A Meta-AnalysisAIDS Research and Human Retroviruses, 2000
- CD4 cell count as a surrogate endpoint in HIV clinical trialsAIDS, 1998
- Increasing efficiency from censored survival data by using random effects to model longitudinal covariatesStatistical Methods in Medical Research, 1998
- Surrogate End Points in Clinical Trials: Are We Being Misled?Annals of Internal Medicine, 1996
- Surrogate and auxiliary endpoints in clinical trials, with potential applications in cancer and aids researchStatistics in Medicine, 1994
- Surrogate endpoints in clinical trials: Definition and operational criteriaStatistics in Medicine, 1989